A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.
Phase 1
Active, not recruiting
- Conditions
- EpilepsyMedDRA version: 21.0Level: PTClassification code: 10015037Term: Epilepsy Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2022-502638-17-00
- Lead Sponsor
- Trevena Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antiepileptic effects of CP045-1004 in phase I trials?
How does CP045-1004 compare to standard-of-care antiepileptic drugs in early-phase safety and efficacy profiles?
Are there specific biomarkers associated with response to CP045-1004 in epilepsy patient subpopulations?
What adverse event management strategies are employed in Trevena Inc.'s phase I CP045-1004 trial for epilepsy?
What related compounds or combination therapies are being explored alongside CP045-1004 for epilepsy treatment?